Research Analysis of Neuralstem, Inc. (NASDAQ:CUR)


Neuralstem, Inc. (NASDAQ:CUR) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.

Neuralstem, Inc. (NASDAQ:CUR) lost -34.95 Percent and closed its previous trading session at $2.01. The stock traded with the average Volume of 1.35 Million at the end of last session.

Neuralstem, Inc. (NASDAQ:CUR) has the Market Capitalization of 29.63 Million. The Stock has its 52-week High of $6.60 and 52-Week Low of $0.88 and it touched its 52-week high on 06/26/17 and 52-Week Low on 11/15/17.

The company reported its last earnings Actual EPS of $-0.36/share. While, the analyst predicted that the company could provide an EPS of $-0.73/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.37/share which shows an Earnings Surprise of 50.7 Percent.

The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 69.85% where SMA50 and SMA200 are 59.5% and -38.21% respectively.

The company shows its Return on Assets (ROA) value of -100.3%. The Return on Equity (ROE) value stands at -176%.

Neuralstem, Inc. (NASDAQ:CUR) currently has a Weekly Volatility of 43.07% percent while its Monthly Volatility is at 17.66% percent. While talking about Performance of the Stock, Neuralstem, Inc. currently has a Weekly performance of 81.08%, monthly performance percentage is 70.34 percent, Quarterly performance is 70.34 percent, 6 months performance shows a percent value of -62.29% and Yearly Performance is -39.39 percent.

Company Profile:

NEURALSTEM’s patent-protected technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The Company expects that its first Investigational New Drug application will be for the treatment of Ischemic Paraplegia, a form of paraplegia that sometimes results from the surgery to repair aortic aneurysms and for which there is no effective treatment.